Infographic: Solving the challenges of immuno-oncology trials
The booming interest in new targeted therapies represents a changing of the guard in cancer treatment, from the former one-size-fits-all approach to a more personalised methodology. As a result, targeted therapies now dominate the global R&D pipeline.
However the process of bringing the therapies to market, optimising speed while managing risk and cost, is a complex one and presents new challenges for pharma.
What are the challenges that the new immuno-oncology drugs present and how can they be addressed? The infographic below highlights these complexities and the possible solutions to them.
Would you like more in-depth information on the challenges of immuno-oncology clinical trials?
For further content on pharmaphorum relating to this topic please click here.